Cancer-driving BRAF mutations (V600E/K) are found in 40-60% of melanoma patient tumors, and BRAF-inhibitor agents, dabrafenib and vemurafenib, have extended median patient survival by 5-6 months [4]. Here, BRAF is linked to cancer.